Wissenschaftliche Arbeiten

Doç. Dr. Muhammed Mustafa Atcı

104 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15725-9 PMID 41691201 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Perioperative FLOT versus Definitive 50.4 Gy Chemoradiotherapy in Siewert II Esophagogastric Junction Adenocarcinoma: A Multicenter Retrospective Cohort Study

    Cancer Management and Research, 2026

    DOI 10.2147/cmar.s583473 PMID 42038552 Frei zugänglicher VolltextQuelle: OpenAlex

  3. Expression and prognostic importance of lymphocyte activation gene 3 and CD73 in advanced or metastatic hepatocellular carcinoma

    Journal of International Medical Research, 2026

    DOI 10.1177/03000605251386599 PMID 41521150 Frei zugänglicher VolltextQuelle: OpenAlex

  4. Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature

    Clinical Genitourinary Cancer, 2026

    DOI 10.1016/j.clgc.2026.102594 PMID 42349378 Quelle: OpenAlex

  5. De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study

    The Breast, 2026

    DOI 10.1016/j.breast.2026.104838 PMID 42309024 Frei zugänglicher VolltextQuelle: OpenAlex

  6. Prognostic factors and survival outcomes in older adults with extensive-stage small cell lung cancer: A multicenter retrospective cohort study

    Medicine, 2026

    DOI 10.1097/md.0000000000048711 PMID 42116366 Frei zugänglicher VolltextQuelle: OpenAlex

  7. Prognostic value of PSMA PET–derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

    Cancer Imaging, 2026

    DOI 10.1186/s40644-026-01036-6 PMID 42063136 Frei zugänglicher VolltextQuelle: OpenAlex

  8. Inflammatory and Nutritional Indices as Prognostic Markers in Locally Advanced Gastric Cancer Treated with Neoadjuvant FLOT: A Retrospective Multicenter Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15072574 PMID 41976874 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  9. Neoadjuvant anthracycline-free versus anthracycline-containing chemotherapy combined with dual HER2 blockade in HER2-positive breast cancer: a real-world comparative study

    Breast Cancer Research, 2026

    DOI 10.1186/s13058-026-02312-w PMID 42210329 Frei zugänglicher VolltextQuelle: OpenAlex

  10. Neoadjuvant Pertuzumab in Breast Cancer and Associated Prognostic Factors

    European Archives of Medical Research, 2026

    DOI 10.14744/eamr.2025.35682 Frei zugänglicher VolltextQuelle: OpenAlex

  11. Efficacy and tolerability of CDK 4/6 inhibitors in HR-positive HER2-negative de novo metastatic breast cancer patients aged ≥ 70 years

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16430-3 PMID 42351034 Frei zugänglicher VolltextQuelle: OpenAlex

  12. Maintenance pemetrexed after platinum pemetrexed chemotherapy and survival outcomes in malignant pleural mesothelioma in a multicenter real world study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-61625-0 PMID 42457832 Frei zugänglicher VolltextQuelle: OpenAlex

  13. Bevacizumab or Aflibercept in Combination with Second-Line FOLFIRI after Progression on FOLFOX Plus Bevacizumab in Metastatic Colorectal Cancer: A Comparative Study

    Journal of Cancer, 2026

    DOI 10.7150/jca.138530 PMID 42807710 Frei zugänglicher VolltextQuelle: OpenAlex

  14. Treatment outcomes of sunitinib and/or pazopanib in advanced alveolar soft part sarcoma: A Turkish Oncology Group (TOG) study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-29276-9 PMID 41315659 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  15. Factors affecting survival and prognosis in extensive stage small cell lung cancer

    BMC Pulmonary Medicine, 2025

    DOI 10.1186/s12890-025-03625-w PMID 40200252 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  16. Comparison of clinical and prognostic characteristics of patients with classic and AIDS-related Kaposi sarcoma: A single-center experience

    Medicine, 2025

    DOI 10.1097/md.0000000000043576 PMID 40760592 Frei zugänglicher VolltextQuelle: OpenAlex

  17. Distribution of side effects of anti-EGFR treatments in patients with metastatic colorectal cancer and evaluation of their relationship with survival

    Anti-Cancer Drugs, 2025

    DOI 10.1097/cad.0000000000001755 PMID 40626459 1 Zitation (Europe PMC) Quelle: OpenAlex

  18. Bevacizumab Efficacy and Tolerability in Patients with Metastatic Platinum-Sensitive Ovarian Cancer Beyond Progression

    Cancer Management and Research, 2025

    DOI 10.2147/cmar.s531276 PMID 40861079 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  19. The Effect of Total Neoadjuvant Treatment on Pathological Response and Survival in Locally Advanced Rectal Cancer: A Single Center Experience

    Clinical Colorectal Cancer, 2025

    DOI 10.1016/j.clcc.2025.05.001 PMID 40537334 1 Zitation (Europe PMC) Quelle: OpenAlex

  20. Advancing prognostic precision in unplanned oncology admissions: the promise of the PROMISE–CTI score

    The Lancet Regional Health - Europe, 2025

    DOI 10.1016/j.lanepe.2025.101336 PMID 40530357 Frei zugänglicher VolltextQuelle: OpenAlex

  21. Analysis of the impact of IMDC score parameters on patients with metastatic clear cell renal cell carcinoma

    Biomarkers in Medicine, 2025

    DOI 10.1080/17520363.2025.2589382 PMID 41243728 Quelle: OpenAlex

  22. Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-87553-z PMID 39863702 Frei zugänglicher VolltextQuelle: OpenAlex

  23. Distinguishing between carcinoid tumors and hamartomas: the diagnostıc value of FDG PET/CT

    The Egyptian Journal of Radiology and Nuclear Medicine, 2025

    DOI 10.1186/s43055-025-01629-4 Frei zugänglicher VolltextQuelle: OpenAlex

  24. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

    BMC Cancer, 2024

    DOI 10.1186/s12885-023-11783-5 PMID 38166764 6 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  25. Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in gastric cancer: Pathological regression grade and its relationship to clinical outcome

    Indian Journal of Cancer, 2024

    DOI 10.4103/ijc.ijc_1283_20 PMID 39960699 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  26. Factors Affecting Recurrence and Survival in Stage IIA Colon Cancer Patients

    Oncology, 2024

    DOI 10.1159/000540334 PMID 39008971 3 Zitationen (Europe PMC) Quelle: OpenAlex

  27. Evaluation of ixabepilone efficacy and tolerability in metastatic breast cancer

    Medicine, 2024

    DOI 10.1097/md.0000000000040649 PMID 39809199 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  28. The impact of body mass index on the progression-free survival of CDK 4/6 inhibitors in metastatic breast cancer patients

    Future Oncology, 2024

    DOI 10.1080/14796694.2024.2402212 PMID 39316555 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  29. The Optimal Treatment Approaches and Prognostic Factors In Elderly Patients with Advanced Stage Biliary Tract Tumors

    Acta Oncologica Turcica, 2023

    DOI 10.5505/aot.2023.03708 Frei zugänglicher VolltextQuelle: OpenAlex

  30. Major and minor salivary gland cancers: A multicenter retrospective study

    Head & Neck, 2023

    DOI 10.1002/hed.27376 PMID 37084179 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  31. Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study

    Neoplasma, 2023

    DOI 10.4149/neo_2022_221004n984 PMID 36620878 Frei zugänglicher VolltextQuelle: OpenAlex

  32. Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens

    Oncology Letters, 2023

    DOI 10.3892/ol.2023.13795 PMID 37123028 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  33. Initial Albumin-Bilirubin Grade as a Prognostic Indicator of Pancreatic Cancer with Liver Metastasis

    Journal of Oncological Sciences, 2023

    DOI 10.37047/jos.2021-87242 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  34. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-03984-5 PMID 35381885 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  35. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

    Current Medical Research and Opinion, 2022

    DOI 10.1080/03007995.2022.2108619 PMID 35916475 4 Zitationen (Europe PMC) Quelle: OpenAlex

  36. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal carcinoma

    Bosnian Journal of Basic Medical Sciences, 2022

    DOI 10.17305/bjbms.2021.7069 PMID 35460397 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  37. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?

    Expert Review of Anticancer Therapy, 2022

    DOI 10.1080/14737140.2022.2076670 PMID 35543015 3 Zitationen (Europe PMC) Quelle: OpenAlex

  38. Effect of Adjuvant Chemotherapy in Stage III Cervical Cancer Patients Treated with Concurrent Chemoradiation: A Multicenter Study

    Oncology Research and Treatment, 2022

    DOI 10.1159/000521980 PMID 35034017 3 Zitationen (Europe PMC) Quelle: OpenAlex

  39. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04252-2 PMID 36048274 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  40. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

    Future Oncology, 2022

    DOI 10.2217/fon-2022-0083 PMID 35734870 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  41. Efficacy of Imatinib on Advanced and Refractory Desmoid Tumors: A Retrospective Study

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2021-87391 Frei zugänglicher VolltextQuelle: OpenAlex

  42. Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study.

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.4_suppl.202 Quelle: OpenAlex

  43. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

    Anti-Cancer Drugs, 2022

    DOI 10.1097/cad.0000000000001310 PMID 35703239 3 Zitationen (Europe PMC) Quelle: OpenAlex

  44. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer

    Journal of Chemotherapy, 2022

    DOI 10.1080/1120009x.2022.2026125 PMID 35037592 15 Zitationen (Europe PMC) Quelle: OpenAlex

  45. Dynamic changes in systemic immune‐inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy

    Asia-Pacific Journal of Clinical Oncology, 2022

    DOI 10.1111/ajco.13784 PMID 35538045 17 Zitationen (Europe PMC) Quelle: OpenAlex

  46. A new biomarker for lung metastasis in non-seminomatous testicular cancer: De Ritis Ratio

    Aktuelle Urologie, 2022

    DOI 10.1055/a-1926-9698 PMID 36302549 3 Zitationen (Europe PMC) Quelle: OpenAlex

  47. The Relationship Between Poor Glycaemic Control and Risk Factors in Patients with Type 2 Diabetes Mellitus

    Eurasian Journal of Medical Advances, 2022

    DOI 10.14744/ejma.2022.87597 3 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  48. Effects of a COVID-19 Pandemic on Breast Cancer Management

    European Archives of Medical Research, 2022

    DOI 10.4274/eamr.galenos.2021.92063 Frei zugänglicher VolltextQuelle: OpenAlex

  49. Efficacy of Trastuzumab and Potential Risk Factors on Survival in Patients with HER2-Positive Metastatic Gastric Cancer

    Future Oncology, 2021

    DOI 10.2217/fon-2021-0398 PMID 34323116 2 Zitationen (Europe PMC) Quelle: OpenAlex

  50. Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study

    European Journal of Breast Health, 2021

    DOI 10.4274/ejbh.galenos.2020.6346 PMID 33870111 11 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex